Enanta Pharma

ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

United Airlines Holdings

News

Markets

Analyst Ratings

Trading Ideas

AAOI

ALGT

BBAI

ENTA

ONDS

SKYW

TTGT

United Airlines To Rally More Than 20%? Here Are Top Analyst Forecasts For Monday

crowdstrike shutter2

Price Target

BHLB

BTCS

CRWD

DXLG

OPRX

CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday

Medicine,Doctor,Touching,Electronic,Medical,Record,On,Tablet.,Dna.,Digital

Biotech

Health Care

General

Enanta Pharmaceuticals&#39; EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms while maintaining a favorable safety profile. EDP-323 offers potential as a once-daily oral treatment.

Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharmaceuticals Inc

Entain PLC

Press Releases

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Enanta Pharmaceuticals to Appeal Ruling Related to '953 Patent Infringement Lawsuit

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Alector

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Atossa Therapeutics

C4 Therapeutics

Coherus BioSciences

Coya Therapeutics

Editas Medicine

Fate Therapeutics

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

HilleVax

Immunic

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Lexeo Therapeutics

Lyell Immunopharma

Macrogenics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

RAPT Therapeutics

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences

Tango Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Vigil Neuroscience

Exagen

JMP Securities

HC Wainwright & Co.

Baird

JP Morgan

Oppenheimer

Comments

Enanta Pharma

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell